Home Newsfeeds HC Wainwright & Co. Downgrades Oramed Pharmaceuticals to Neutral

HC Wainwright & Co. Downgrades Oramed Pharmaceuticals to Neutral

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) from Buy to Neutral.

byBenzinga Newsdesk

January 17, 2023

1 minute read

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) from Buy to Neutral.

Will Rent Prices Finally Cool Down? Key Indicator Offers Hope, But Major Cities Remain Unaffordable

By Natan Ponieman

June 4, 2:35 PM

Rent prices may finally drop as vacancies increase, pushing landlords to lower rates and tenants to stay longer in their units.

SCHH

Why Lung Disease Focused Stock Insmed Is Trading Higher Today?

By Vandana Singh

September 5, 12:34 PM

Insmed Incorporated (NASDAQ: INSM) shares are trading higher after the company released topline results from its Phase 3 ARISE study of ARIKAYCE in patients with newly diagnosed or recurrent nontuberculous mycobacterial (NTM) lung infection caused by Mycobacterium avium complex (MAC)

INSM